Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness analysis and budgetary impact of anidulafungin treatment for patients with candidemia and other forms of invasive candidiasis in Brazil.
Rev Inst Med Trop Sao Paulo. 2023; 65:e9.RI

Abstract

Candidemia and other forms of invasive candidiasis (C/IC) are serious conditions, especially for immunosuppressed individuals with prolonged hospitalization in intensive care units (ICU). This study analyzed the incremental cost-effectiveness and budgetary impact (BI) of treatment for IC with anidulafungin compared to amphotericin B lipid complex (ABLC) and amphotericin B deoxycholate (ABD) or conventional amphotericin B (CAB), in the Brazilian Unified Health System (SUS). A decision model was conducted with a time horizon of two weeks from the perspective of SUS. The primary effectiveness endpoints were survival and treatment response rate. All patients were followed up until successful therapy or death. BI analysis was performed based on the measured demand method. A five-year time horizon was adopted based on the number of hospitalizations (per 1,000 hospitalizations). For effectiveness measured in the successful response rate (SRR), anidulafungin dominated the ABLC and ABD formulations. In the results of the analysis with the effectiveness measured according to survival, anidulafungin had a better cost-effectiveness ratio (R$988.26/survival) compared to ABD (R$16,359.50/survival). The BI estimate related to the incorporation of anidulafungin suggests savings of approximately 148 million reais in 5 years when comparing it to ABD. The economic evaluation of anidulafungin and its comparators found it to be cost-effective. The consensus of international scientific societies recommends it as a first-line drug for IC, and its incorporation by SUS would be important.

Links

PMC Free PDF

Authors+Show Affiliations

Vianna CMM
Universidade do Estado do Rio de Janeiro, Instituto de Medicina Social, Departamento de Política, Planejamento e Administração em Saúde, Rio de Janeiro, Rio de Janeiro, Brazil.
Mosegui GBG
Universidade Federal Fluminense, Instituto de Saúde Coletiva, Departamento de Saúde e Sociedade, Niterói, Rio de Janeiro, Brazil.
Rodrigues MPDS
Marinha do Brasil, Farmácia, Rio de Janeiro, Rio de Janeiro, Brazil.

MeSH

HumansCandidemiaAnidulafunginBrazilCost-Effectiveness AnalysisCandidiasis, Invasive

Pub Type(s)

Journal Article

Language

eng

PubMed ID

36722671

Citation

Vianna, Cid Manso de Mello, et al. "Cost-effectiveness Analysis and Budgetary Impact of Anidulafungin Treatment for Patients With Candidemia and Other Forms of Invasive Candidiasis in Brazil." Revista Do Instituto De Medicina Tropical De Sao Paulo, vol. 65, 2023, pp. e9.
Vianna CMM, Mosegui GBG, Rodrigues MPDS. Cost-effectiveness analysis and budgetary impact of anidulafungin treatment for patients with candidemia and other forms of invasive candidiasis in Brazil. Rev Inst Med Trop Sao Paulo. 2023;65:e9.
Vianna, C. M. M., Mosegui, G. B. G., & Rodrigues, M. P. D. S. (2023). Cost-effectiveness analysis and budgetary impact of anidulafungin treatment for patients with candidemia and other forms of invasive candidiasis in Brazil. Revista Do Instituto De Medicina Tropical De Sao Paulo, 65, e9. https://doi.org/10.1590/S1678-9946202365009
Vianna CMM, Mosegui GBG, Rodrigues MPDS. Cost-effectiveness Analysis and Budgetary Impact of Anidulafungin Treatment for Patients With Candidemia and Other Forms of Invasive Candidiasis in Brazil. Rev Inst Med Trop Sao Paulo. 2023;65:e9. PubMed PMID: 36722671.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness analysis and budgetary impact of anidulafungin treatment for patients with candidemia and other forms of invasive candidiasis in Brazil. AU - Vianna,Cid Manso de Mello, AU - Mosegui,Gabriela Bittencourt Gonzalez, AU - Rodrigues,Marcus Paulo da Silva, Y1 - 2023/01/30/ PY - 2022/09/09/received PY - 2022/12/13/accepted PY - 2023/2/1/entrez PY - 2023/2/2/pubmed PY - 2023/2/3/medline SP - e9 EP - e9 JF - Revista do Instituto de Medicina Tropical de Sao Paulo JO - Rev Inst Med Trop Sao Paulo VL - 65 N2 - Candidemia and other forms of invasive candidiasis (C/IC) are serious conditions, especially for immunosuppressed individuals with prolonged hospitalization in intensive care units (ICU). This study analyzed the incremental cost-effectiveness and budgetary impact (BI) of treatment for IC with anidulafungin compared to amphotericin B lipid complex (ABLC) and amphotericin B deoxycholate (ABD) or conventional amphotericin B (CAB), in the Brazilian Unified Health System (SUS). A decision model was conducted with a time horizon of two weeks from the perspective of SUS. The primary effectiveness endpoints were survival and treatment response rate. All patients were followed up until successful therapy or death. BI analysis was performed based on the measured demand method. A five-year time horizon was adopted based on the number of hospitalizations (per 1,000 hospitalizations). For effectiveness measured in the successful response rate (SRR), anidulafungin dominated the ABLC and ABD formulations. In the results of the analysis with the effectiveness measured according to survival, anidulafungin had a better cost-effectiveness ratio (R$988.26/survival) compared to ABD (R$16,359.50/survival). The BI estimate related to the incorporation of anidulafungin suggests savings of approximately 148 million reais in 5 years when comparing it to ABD. The economic evaluation of anidulafungin and its comparators found it to be cost-effective. The consensus of international scientific societies recommends it as a first-line drug for IC, and its incorporation by SUS would be important. SN - 1678-9946 UR - https://www.unboundmedicine.com/medline/citation/36722671/Cost-effectiveness_analysis_and_budgetary_impact_of_anidulafungin_treatment_for_patients_with_candidemia_and_other_forms_of_invasive_candidiasis_in_Brazil. DB - PRIME DP - Unbound Medicine ER -